We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
HH Biotechnology Holdings Company (CE) | USOTC:HHBT | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0003 | 0.00 | 01:00:00 |
|
UNITED STATES
|
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
|
Washington, D.C. 20549
|
|
|
|
|
|
FORM 15
|
|
|
|
|
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12 (g)
|
||||||||||||
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO
FILE
|
||||||||||||
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES ACT OF
1934.
|
|
Commission File
Number
|
0-23015
|
|
||
|
HH Biotechnology Holdings Company
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
C
Site 25-26F Presidential Bldg.,
No.
69 Heping North Street,
Heping
District, Shenyang 110003, PRC
|
|
|
0086-24-22813888
|
|
|
(Address,
including zip code, and telephone number, including
|
|
|
area
code, of registrant’s principal executive
offices)
|
|
|
Common Stock, par value $0.001 per share (“Common
Stock”)
|
|
|
(Title
of each class of securities covered by this Form)
|
|
|
||
|
None
|
|
|
(Title
of all other classes of securities for which a duty to file
reports
|
|
|
under
section 13(a) or 15(d) remains)
|
|
|
||||||||||||
Please
place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file
reports:
|
||||||||||||
|
||||||||||||
|
Rule
12g-4(a)(1)
|
X
|
|
|||||||||
|
Rule
12g-4(a)(2)
|
|
|
|||||||||
|
Rule
12h-3(b)(1)(i)
|
|
|
|||||||||
|
Rule
12h-3(b)(1)(ii)
|
|
|
|||||||||
|
Rule
15d-6
|
|
|
|||||||||
|
Rule
15d-22(b)
|
|
|
|||||||||
|
||||||||||||
Approximate number
of holders of record as of the certification or notice date:
151
|
||||||||||||
Pursuant to the
requirements of the Securities Exchange Act of 1934, Caspian
Services, Inc. has caused this
|
||||||||||||
certification/notice
to be signed on its behalf by the undersigned duly authorized
person
|
||||||||||||
|
||||||||||||
|
||||||||||||
Date:
|
February 15, 2017
|
|
By:
|
/s/
Sheng Jiang
|
||||||||
|
Sheng
Jiang
|
|||||||||||
|
Chief
Executive Officer
|
1 Year HH Biotechnology (CE) Chart |
1 Month HH Biotechnology (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions